Pharmaceutical Technology

MAY 12, 2023

The Technical University of Denmark (DTU) has announced that an international scientific team has developed a CRISPR-based drug candidate that targets E coli directly and leaves the microbiome intact. The team then engineered the phages through gene editing to improve their targeting ability.

Development 246

Development Bacteria Research Drugs 246

Pharmaceutical Technology

MARCH 29, 2023

Regeneron Pharmaceuticals has collaborated with Sonoma Biotherapeutics to discover, develop and commercialise new regulatory T cell (Treg) therapies for autoimmune diseases. The two companies will together research and develop T cell therapies for Crohn’s disease and ulcerative colitis, as well as two other undisclosed indications.

Development 245

Development Gene Therapy Gene Production 245

Medical Xpress

MAY 16, 2023

Inspired by sutures developed thousands of years ago, MIT engineers have designed "smart" sutures that can not only hold tissue in place, but also detect inflammation and release drugs.

Engineer 127

Engineer Drugs Development 127

Pharmaceutical Technology

APRIL 6, 2023

Ginkgo Bioworks has strengthened its end-to-end R&D capabilities in gene therapy with the purchase of adeno-associated virus (AAV) capsid discovery and engineering assets from StrideBio, for an undisclosed sum. The new capabilities and IP will be incorporated under Ginkgo’s end-to-end AAV gene therapy development platform.

Engineer 130

Engineer Gene Therapy Gene Manufacturing 130

Medical Xpress

MARCH 1, 2025

Studies reveal that people with Down syndrome (DS) have over a 90% lifetime risk of developing dementia caused by Alzheimer's disease (AD) as they age.

Engineer 93

Engineer Development Research 93

Medical Xpress

FEBRUARY 21, 2025

Researchers from Carnegie Mellon University and Allegheny Health Network have developed a new method for deep brain stimulation. The findings are published in the Journal of Neural Engineering.

Engineer 95

Engineer Development Research 95

AuroBlog - Aurous Healthcare Clinical Trials blog

MAY 19, 2024

Different types of brain cells could age at different speeds, and that may help explain the development of Alzheimer’s disease.

Engineer 246

Engineer Development Clinical Trials Clinical Trials 246

Pharma Mirror

MAY 19, 2021

Rashedi Hassan holds a Diploma in Engineering from Dhaka Polytechnic Institute. With more than 18. The post Rashedi Hassan takes over Sales & Marketing management of Telstar’s subsidiary in Bangladesh appeared first on Pharma Mirror Magazine.

Sales 246

Sales Marketing Engineer Life Science 246

Pharmaceutical Technology

OCTOBER 13, 2022

Inceptor Bio has partnered with cell engineering technology company Avectas to improve CAR-T cell therapies’ development and manufacturing to treat solid tumours. Under the collaboration deal, Inceptor Bio will use the Solupore technology from Avectas instead of electroporation for engineering T cells to yield a healthier T cell.

Development 147

Development Engineer Gene Therapy Gene 147

Pharmaceutical Technology

DECEMBER 22, 2023

Ono has signed an agreement with EVQLV to utilise its AI-powered antibody design engine for the development of new antibody drugs.

Antibody 130

Antibody Development Engineer Drugs 130

STAT News

JULY 28, 2022

In biopharma research and development, laboratory data now exist in petabytes. Now common on biotech job boards are positions like cloud engineer, data scientist, automation engineer, software engineer, machine learning engineer, and computational biologist. Algorithms are the path to discovering new materials.

Engineer 105

Engineer Scientist Vaccination Vaccine 105

Pharmaceutical Technology

JULY 13, 2023

Tenpoint Therapeutics has raised Series A funds of $70m for developing engineered cell-based therapies to reverse vision loss.

Development 130

Development Engineer 130

Medical Xpress

APRIL 22, 2023

Repairing or replacing injured tendons or similar load-bearing tissues represents one of the major challenges in clinical medicine. Natural tendons are water-rich tissues exhibiting outstanding mechanical strength and durability.

Engineer 109

Engineer Development Medicine 109

Pharmaceutical Technology

AUGUST 11, 2022

GentiBio and Bristol Myers Squibb (BMS) have signed a multi-year partnership agreement for developing new engineered Treg therapies for inflammatory bowel disease (IBD) patients. These therapies will be developed for re-instating immune tolerance and repairing tissue in IBD.

Development 130

Development Engineer Gene Therapy Clinical Trials 130

Pharmaceutical Technology

SEPTEMBER 8, 2024

Interferon alfa-2b is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase II for Genital Warts (Condylomata Acuminata).

Genetic Engineering 100

Genetic Engineering Engineer Genetics Clinical Development 100

Pharmaceutical Technology

MAY 5, 2023

TFF Pharmaceuticals and the National Institute of Environmental Health Sciences (NIEHS) have signed an agreement for the development of dry powder formulations of high molecular weight hyaluronan (HMW-HA) for respiratory diseases.

Development 162

Development In-Vivo In-Vitro Engineer 162

Pharmaceutical Technology

SEPTEMBER 29, 2022

Scribe Therapeutics and Sanofi have signed a strategic partnership to expedite the development of breakthrough clustered regularly interspaced short palindromic repeats (CRISPR)-based cell therapies for cancer. Scribe is also entitled to receive potential payments worth over $1bn on meeting development and commercial milestones.

Development 130

Development In-Vivo Genomics Genome 130

Pharmaceutical Technology

JUNE 10, 2023

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Buy the report here.

Genetic Engineering 100

Genetic Engineering Engineer Genetics Clinical Trials 100

Pharmaceutical Technology

JUNE 10, 2023

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Buy the report here.

Genetic Engineering 100

Genetic Engineering Engineer Genetics Clinical Trials 100

Pharmaceutical Technology

JULY 20, 2022

Avista Therapeutics, a University of Pittsburgh Medical Center (UPMC) spinout, has entered a collaboration with Roche for developing new AAV gene therapy vectors for eyes. The post Avista and Roche to develop gene therapy vectors for eyes appeared first on Pharmaceutical Technology.

Gene Therapy 147

Gene Therapy Gene Development In-Vivo 147

Pharmaceutical Technology

JANUARY 30, 2024

Synthekine will receive an upfront payment of $40 million for its preclinical cytokine engineering clinical expertise.

Engineer 130

Engineer Development 130

Pharmaceutical Technology

APRIL 14, 2023

The company and the researchers, with Professor Krishanu Saha as principal investigator (PI) and Dr Christian Capitini as co-PI, will develop a GD2 CAR T-cell therapeutic candidate to treat neuroblastoma, a cancer type that generally affects young children.

In-Vivo 264

In-Vivo Gene Therapy In-Vitro Engineer 264

Pharmaceutical Technology

DECEMBER 19, 2022

With the latest development, Sanofi will licence a NK cell engager programme that acts on B7H3 from the antibody-based NK cell engager therapeutics (ANKET) platform of Innate. On choosing the candidate, the company will oversee the complete development, production and marketing.

Development 264

Development Engineer Clinical Trials Clinical Trials 264

Pharmaceutical Technology

OCTOBER 12, 2022

Nimbus Therapeutics and Eli Lilly and Company (Lilly) have signed a research partnership and licence agreement to develop and market new therapies that activate a specific AMPK isoform to treat metabolic diseases. The company will lead the research activities, while Lilly will undertake the global development and marketing activities.

Development 130

Development Protein Engineer Drugs 130

Pharmaceutical Technology

SEPTEMBER 22, 2022

Abpro has entered a strategic collaboration with Celltrion for the global development and commercialisation of the former's antibody therapy, a t-cell engager known as ABP 102. The cancer molecule will be developed for treating patients with HER2+ cancer, including gastric, pancreatic and breast cancer.

Antibody 130

Antibody Development Bioinformatics In-Vitro 130

Pharmaceutical Technology

APRIL 28, 2023

Generate Biomedicines has signed a co-development and commercialisation agreement with the University of Texas MD Anderson Cancer Center to expedite the development of new protein therapeutics for oncology using generative AI. TRACTION is a part of the therapeutics discovery division of MD Anderson.

Development 130

Development Clinical Trials Clinical Trials Protein 130

Pharmaceutical Technology

JULY 25, 2022

According to Tom Lenaerts, Head of Global Process Engineering at Datwyler, this transformation will reshape the entire healthcare ecosystem. Digital technologies will be utilized throughout drug development, production, packaging and delivery for increased process efficiency and improved product quality.

Engineer 286

Engineer Packaging Packaging Production 286

Pharmaceutical Technology

APRIL 3, 2023

Innate Pharma has signed an exclusive licence agreement with Takeda to enable research and development of antibody drug conjugates (ADCs) against an undisclosed target, primarily focusing on coeliac disease. In addition, Innate will receive royalties on possible net sales of any commercial product to be developed under the licence.

Development 130

Development Antibody Pharma Production Engineer 130

Pharmaceutical Technology

APRIL 11, 2023

Biotechnology company CTRL Therapeutics has announced $10m in seed financing to boost the development of a next-generation cell therapy platform to treat solid tumours. The platform is being developed using inputs from tumour-infiltrating lymphocyte (TIL) therapies.

Development 130

Development Gene Therapy Engineer Clinical Development 130

Pharmaceutical Technology

APRIL 20, 2023

The funds will support Maxion’s KnotBody platform to develop antibodies to treat autoimmune diseases. As per the company, this allows for a longer half-life in the body and gives the ability for further biomolecular engineering. As per Maxion, there are more than 80 types of autoimmune conditions.

Development 130

Development Antibody Engineer Clinical Trials 130

Pharmaceutical Technology

APRIL 13, 2023

ALE.F02 is being developed for the treatment of advanced kidney, lung and liver fibrosis while ALE.C04 is a potential treatment to target CLDN1-positive tumours. The proceeds from the funding round will also be used for the development of the CLDN1 platform to engineer CLDN1 antibody-drug conjugates (ADC) and bispecific antibodies.

Medicine 130

Medicine Development Antibody Engineer 130

Pharmaceutical Technology

DECEMBER 14, 2022

Merck and Synplogen have signed a non-binding Memorandum of Understanding (MoU) to expedite the development and manufacturing of viral vector-based gene therapy applications. The firms intend to merge their expertise to provide simplified viral vector gene therapy development, production and testing in Japan.

Gene Therapy 130

Gene Therapy Gene Development Manufacturing 130

BioPharma Reporter

AUGUST 21, 2024

A team of scientists from the universities of Glasgow and Tel Aviv has developed a groundbreaking method to transform the brain parasite Toxoplasma gondii into a potential vehicle for delivering therapeutic treatments directly to brain cells.

Drug Delivery Systems 97

Drug Delivery Systems Drug Delivery Scientist Engineer 97

Pharmaceutical Technology

APRIL 17, 2023

Prometheus Biosciences uses precision medicine to discover, develop and commercialise new therapeutic and companion diagnostic products to treat immune-mediated diseases. Merck has signed a definitive agreement to buy clinical-stage biotechnology firm Prometheus Biosciences for $10.8bn, strengthening its immunology pipeline.

Engineer 262

Engineer Trials Antibody Development 262

Pharmaceutical Technology

NOVEMBER 29, 2022

Researchers at City of Hope in the US have developed a new potential therapy to treat glioblastoma multiforme (GBM), a kind of brain cancer. These viruses are engineered genetically for killing cancer. The post City of Hope researchers develop new brain cancer therapy appeared first on Pharmaceutical Technology.

Development 130

Development Research Antibody Engineer 130

XTalks

JANUARY 30, 2025

In 2020, the US Food and Drug Administration (FDA) issued a Guidance for Industry recommending that sponsors include plans for developing age-appropriate formulations of drug products in instances where adult formulations may not be suitable for paediatric patients.

Manufacturing 52

Manufacturing Development Compliance Production 52

Pharmaceutical Technology

JANUARY 13, 2023

Being co-developed and co-marketed by Daiichi Sankyo along with AstraZeneca , Enhertu is a specifically engineered HER2-directed antibody-drug conjugate (ADC).

HR 321

HR Trials Engineer Clinical Trials 321